Mary Kay Inc. Earns Several Awards for Work in Business, COVID-19 Response and Sustainability Efforts
In 2021, Mary Kay Inc. continued its decades-long commitment to enriching the lives of women around the globe, manufacturing irresistible products and building healthier, more sustainable communities even in response to COVID-19. In recognition of Mary Kay’s achievements in the last six months, the brand has taken home several coveted awards in the business, corporate citizenship, and leadership categories from various prestigious organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005163/en/
Mary Kay was named a Silver Globee® Winner in 3 categories at the 13th Annual 2021 Golden Bridge Business and Innovation Awards. (Graphic: Mary Kay Inc.)
The awards, which range from recognition of the brand’s COVID-19 response to accolades for a Mary Kay-produced documentary on the Gulf of Mexico’s preservation efforts, highlight the company’s unwavering business values and its dedication to the principles defined by the brand’s legendary founder, Mary Kay Ash.
Latest awards include:
COVID-19 Response Awards
-
Silver Globee® Winner – 13th Annual 2021
Golden Bridge Business and Innovation Awards
- Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
- Company Response of the Year (Mary Kay Inc.)
- Best Product To Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
-
Gold Globee® Winner – 13th Annual 2021
Golden Bridge Business and Innovation Awards
- Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM)
-
Silver Globee® Winner – 6th Annual 2021 American Best in Business Awards
- Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
- Company Response of the Year (Mary Kay Inc.)
- Best Product to Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
-
Gold Globee® Winner – 6th Annual 2021 American Best in Business Awards
- Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM)
Company Awards
- America's Best Mid-Sized Employers 2021 – Forbes
- “Power of Woman” Award, Mary Kay Ukraine, joint project with Marie Claire - X-RAY Marketing Awards
- The Best Employer 2021, Mary Kay Poland – The Financial Magazine
- “Direct Sales Cosmetic Company Number One Award,” Mary Kay Belarus – “Number One” Annual National Awards
Sustainability Awards
Guardians of the Gulf, an eye-opening documentary that explores the tumultuous relationship between the Gulf of Mexico and the conservationists determined to protect it, has received various awards. Mary Kay Inc., serving as executive producer, with Media One in partnership with The Nature Conservancy, visited the coasts of Texas, Alabama and Mexico to shed light on the often-untold stories of Gulf preservation.
- Silver: Non-Broadcast General-Nature/Wildlife – Telly Awards
- Bronze: Non-Broadcast General-Documentary – Telly Awards
- Best Special Focus Documentary Finalist – LA Femme International Film Festival
- World Remi Award – Worldfest Houston International Film Festival
Leadership Recognition
- “67 Powerful Black Women CEOs And Executives In Corporate America,” Julia Simon, Chief Legal Officer and Corporate Secretary / Sheryl Adkins-Green, Chief Marketing Officer – Business Insider
- “TOP Women CEOs in Ukraine” in Women’s Leadership in the Corporate Sector and Business rating - Viktoriia Zoria-Iatsenko, General Manager, Mary Kay Ukraine – WoMo (The Portal for Working Women)
- “50 Most Valuable Women in Poland,” Ewa Kudlińska-Pyrz, General Manager, Mary Kay Poland – The Financial Magazine
- “The Top 100 Women Leaders In Consumer Products Of 2021,” Allyson Sellers, Vice President of Sales, Mary Kay U.S. – Women We Admire
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005163/en/
Contact information
Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom